Clinical Trial Update: Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab plus olaparib in HRD-deficient metastatic colorectal cancer is in early results with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Olaparib (Olaparib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN